RIGL | Rigel Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	16.85 - 17.76
52 Week Range	7.48 - 29.82
Beta	1.36
Implied Volatility	64.82%
IV Rank	2.55%
Day's Volume	401,902
Average Volume	227,746
Shares Outstanding	17,615,000
Market Cap	301,040,350
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-11-29

Valuation
Profitability
Growth
Health
P/E Ratio	63.30
Forward P/E Ratio	-2.96
EPS	0.27
1YR Price Target	2.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	147
Country	USA
Website	RIGL

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

RIGL's peers: ATNM, FBIO, RVPH, CTIC, OCUP, NBRV, EIGR, PIRS, CDTX, XFOR, MREO, INZY, TERN, LPTX, ZURA, ENVB, EFTR, IMMX, ELEV, DAWN, ABOS, VECT, TCRT

*Chart delayed

Analyzing fundamentals for RIGL we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is very good and Health is frighteningly weak. For more detailed analysis please see RIGL Fundamentals page.

Watching at RIGL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on RIGL Technicals page.